指南与共识重症综合管理与镇静镇痛消化、代谢与肾脏急症

探索欧洲共识:ICU 侵袭性真菌感染治疗挑战与改善机会

Exploring European Consensus About the Remaining Treatment Challenges and Subsequent Opportunities to Improve the Management of Invasive Fungal Infection (IFI) in the Intensive Care Unit.
指南 / 共识 · Mycopathologia · 2024-05-05
一句话结论欧洲改良德尔菲共识:ICU 侵袭性真菌感染高临床怀疑即应先行治疗,β-D-葡聚糖 48 h 内出结果以指导停药。

该改良德尔菲共识由专家组制定 44 条 Likert 量表陈述,覆盖 6 个关键领域,包括 ICU 患者筛查与诊断最低标准、抗真菌治疗启动与终止及减少副作用、未来研究方向;在线调查覆盖英国、德国、西班牙、法国和意大利的重症医学科医师、感染病专家、微生物学家和抗菌药物/ICU 药师,共识阈值设为 75%。5 个月收集期内共收到 335 份回复,29/44(66%)条陈述达极高一致性(≥90%),11/44(25%)条达高一致性(<90% 且 ≥75%),4/44(9%)条未达共识阈值(<75%)。共识强调医生应了解本 ICU 的 IFI 局部发病率及唑类耐药率;高临床怀疑时应立即开始治疗,早于任何诊断检测结果;β-D-葡聚糖检测应在所有 ICU 中心可及,48 h 内出结果以指导经验性抗真菌治疗停止;这些共识陈述与拟议措施可为未来研究优化 ICU IFI 管理提供方向。

要点

  • 共识阈值设为 75%,335 份回复中 29/44(66%)条陈述一致性 ≥90%,11/44(25%)条达 75%–<90%,4/44(9%)条未达阈值。
  • 医生应了解本 ICU 的 IFI 局部发病率及唑类耐药率(共识陈述,未给出具体数值阈值)。
  • 高临床怀疑 IFI 时应立即开始治疗,且早于任何诊断检测结果回报(共识陈述)。
  • β-D-葡聚糖检测应在所有 ICU 中心可及,结果须在 48 h 内出报告,以指导经验性抗真菌治疗的停止(共识陈述)。

适用人群与场景

  • ICU 内侵袭性真菌感染(IFI)患者,主要病原为念珠菌属(Candida spp.)和曲霉属(Aspergillus spp.)。
  • 调查对象为英国、德国、西班牙、法国和意大利的重症医学科医师、感染病专家、微生物学家和抗菌药物/ICU 药师。

诊断标准与关键阈值

  • 共识阈值设为 75%。

处置流程与药物剂量

  • 高临床怀疑 IFI 时应立即开始治疗,且早于任何诊断检测结果回报(共识陈述)。
  • β-D-葡聚糖检测应在所有 ICU 中心可及,结果须在 48 h 内出报告,以指导经验性抗真菌治疗的停止(共识陈述)。

研究设计与关键结果

  • 采用改良德尔菲法,专家组制定 44 条 Likert 量表陈述,覆盖 6 个关键领域:ICU 患者筛查与 IFI 诊断最低标准、抗真菌治疗启动与终止及减少副作用、未来研究方向。
  • 调查通过独立服务商 M3 Global 的订阅者名单以便利抽样分发,覆盖英国、德国、西班牙、法国和意大利的重症医学科医师、感染病专家、微生物学家和抗菌药物/ICU 药师。
  • 5 个月收集期内共收到 335 份回复;29/44(66%)条陈述达极高一致性(≥90%),11/44(25%)条达高一致性(<90% 且 ≥75%),4/44(9%)条未达共识阈值(<75%)。

证据类型、等级与局限

  • 证据类型:改良德尔菲共识调查。
  • 共识阈值设为 75%。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,医生应了解本 ICU 的 IFI 局部发病率及唑类耐药率。
  • 作者认为,高临床怀疑 IFI 时应立即开始治疗,且早于任何诊断检测结果。
  • 作者认为,β-D-葡聚糖检测应在所有 ICU 中心可及,48 h 内出结果以指导经验性抗真菌治疗停止。
  • 作者认为,这些共识陈述与拟议措施可为未来研究优化 ICU IFI 管理提供方向。

指南或共识出处

  • Mycopathologia 发表的欧洲共识:Exploring European Consensus About the Remaining Treatment Challenges and Subsequent Opportunities to Improve the Management of Invasive Fungal Infection (IFI) in the Intensive Care Unit(年份原文未写明)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The global prevalence of invasive fungal infections (IFI) is increasing, particularly within Intensive Care Units (ICU), where Candida spp. and Aspergillus spp. represent the most important pathogens. Diagnosis and management of IFIs becomes progressively challenging, with increasing antifungal resistance and the emergence of rare fungal species. Through a consensus survey focused on assessing current views on how IFI should be managed, the aim of this project was to identify challenges around diagnosing and managing IFIs in the ICU. The current status in different countries and perceived challenges to date amongst a multidisciplinary cohort of healthcare professionals involved in the care of IFI in the ICU was assessed.

METHODS: Using a modified Delphi approach, an expert panel developed 44 Likert-scale statements across 6 key domains concerning patient screening and minimal standards for diagnosis of IFIs in ICU; initiation and termination of antifungal treatments and how to minimise their side effects and insights for future research on this topic. These were used to develop an online survey which was distributed on a convenience sampling basis utilising the subscriber list held by an independent provider (M3 Global). This survey was distributed to intensivists, infectious disease specialists, microbiologists and antimicrobial/ICU pharmacists within the UK, Germany, Spain, France and Italy. The threshold for consensus was set at 75%.

RESULTS: A total of 335 responses were received during the five-month collection period. From these, 29/44 (66%) statements attained very high agreement (≥ 90%), 11/44 (25%) high agreement (< 90% and ≥ 75%), and 4/44 (9%) did not meet threshold for consensus (< 75%).

CONCLUSION: The results outline the need for physicians to be aware of the local incidence of IFI and the associated rate of azole resistance in their ICUs. Where high clinical suspicion exists, treatment should start immediately and prior to receiving the results from any diagnostic test. Beta-D-glucan testing should be available to all ICU centres, with results available within 48 h to inform the cessation of empirical antifungal therapy. These consensus statements and proposed measures may guide future areas for further research to optimise the management of IFIs in the ICU.

来源:Mycopathologia,查看原文。版权归原作者所有。

参考来源

  1. Hoenigl M, Enoch DA, Wichmann D, et al. Exploring European Consensus About the Remaining Treatment Challenges and Subsequent Opportunities to Improve the Management of Invasive Fungal Infection (IFI) in the Intensive Care Unit. Mycopathologia. 2024. PMID: 38704761. doi:10.1007/s11046-024-00852-3

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。